All posts by imreal

Cognosante Awarded DHA Omnibus IV Contract for Translation Science Support and Services


Cognosante, a mission-driven technology company, has been awarded a Defense Health Agency Indefinite Delivery-Indefinite Quantity (IDIQ) multiple award contract to provide knowledge translation services and research and development support to the Department of Defense.

The $10 billion Defense Health Agency Omnibus contract vehicle is intended to enhance warfighter health and readiness by effectively integrating the latest medical knowledge and solutions into the Military Health System. The current iteration, Omnibus IV, builds upon the work of its predecessors by specifically addressing translation science, a specialty field focused on transitioning research into practice. The award positions Cognosante to pursue task orders as a prime contractor under Market Segment 4: Translational Science Support and Services and as a subcontractor for both Market Segment 4 and Market Segment 2: Research and Development Support Services.

“We are thrilled to be among those selected for the DHA Omnibus IV IDIQ,” says Philip Dietz, General Manager of Cognosante’s Military and Veterans Health Business Unit. “This win builds upon our extensive implementation science experience in the Military Health System and offers new opportunities to demonstrate value through impactful work that supports the health and readiness of the warfighter.”

Cognosante currently provides support to the Defense Health Agency Implementation Science Branch in addition to supporting enterprise-wide implementation of high reliability organization principles and practices across the Veterans Health Administration. Dietz continued, “Cognosante is a recognized partner to the Defense Health Agency in its efforts to implement research-back solutions across the Military Health System. We look forward to the opportunity to expand our existing capabilities and infrastructure in service to the DoD and DHA.”

About Cognosante

Cognosante is a mission-driven technology company delivering innovative and transformative solutions that improve the health and safety of Americans. With more than a decade of experience working with state and Federal government agencies, we aim to expand access to care, improve care delivery, deliver solutions addressing social determinants of health and ensure safety and security through multi-faceted technology and customer experience (CX) solutions. Our broad range of capabilities includes enterprise IT and cloud, data science, telehealth, interoperability, public health surveillance, clinical performance, eligibility and enrollment and consumer engagement.

Visit http://www.cognosante.com for more information.

# # #

Share article on social media or email:

AdventHealth to Open First Two Pharmacy Kiosks Locations in Florida


SpotRx Pharmacy Kiosk

AdventHealth is now home to SpotRx pharmacy kiosks to make it convenient and more accessible for patients to fill prescriptions before leaving the doctor’s office. The kiosks will provide acute and chronic medications, over the counter products as well as creams, ointments, eye drops and test strips. The kiosks will not house controlled substances such as diazepam or oxycodone. Patients insert a prescription receipt, and the kiosk dispenses the medication. The SpotRx pharmacy kiosk is currently available at AdventHealth Care Pavilion Westchase in Hillsborough County and will be installed later this year at AdventHealth Care Pavilion Heathbrook in Marion County.

“We are committed to making it easy for our patients by finding innovative ways to deliver health care that fits into busy schedules,” said John Johannessen, Senior Executive Officer of Non-Acute, AdventHealth West Florida Division. “Our partnership with SpotRx provides another time saving convenience at our Care Pavilions so patients can get the care they need and not have to make another stop before they get home.”

With the SpotRx embedded pharmacy model, home delivery is also available. AdventHealth Care Pavilion patients will receive:

  • Convenience of immediate access to prescriptions.
  • Free contactless next-day home delivery for all prescriptions and over-the-counter medications.
  • Instant access to SpotRx pharmacists via kiosk or phone.
  • Coordinated care between clinic provider and the pharmacy ensuring quality of patient care.
  • Follow up care calls from a local SpotRx pharmacist after receiving the prescription.

AdventHealth Care Pavilions provide additional convenient access to patients by integrating multiple health care services into one location. The goal of the Care Pavilion is to focus on making health care easier to access while enhancing the overall patient experience.

“We are excited to partner with AdventHealth and expand patient access to our differentiated pharmacy solutions in Florida. We are additionally pleased to leverage our new hub pharmacy in Tampa to service these clinics,” said Mark Doerr, Chief Executive Officer of MedAvail. “We look forward to serving AdventHealth patients through this collaboration and broadening our footprint in Florida where we see a tremendous opportunity and need for SpotRx.”

SpotRx Pharmacy is the retail pharmacy brand owned and operated by MedAvail in the United States, which deploys and operates the MedAvail MedCenters, its technology-enabled prescription kiosks.

About AdventHealth West Florida Division

The West Florida Division of AdventHealth has some of the nation’s brightest medical minds making lifesaving breakthroughs with surgical pioneers, scientists and researchers using leading edge technology and innovation to deliver our brand of whole-person care. Our network of care includes AdventHealth Carrollwood, AdventHealth Connerton, AdventHealth Dade City, AdventHealth Heart of Florida, AdventHealth Lake Placid, AdventHealth Lake Wales, AdventHealth North Pinellas, AdventHealth Ocala, AdventHealth Sebring, AdventHealth Tampa, AdventHealth Wauchula, AdventHealth Wesley Chapel and AdventHealth Zephyrhills, as well as seven freestanding offsite Emergency Rooms including AdventHealth Belleview ER, AdventHealth Brandon ER, AdventHealth Central Pasco ER, AdventHealth Four Corners ER, AdventHealth Palm Harbor ER, AdventHealth TimberRidge ER, and AdventHealth Westchase ER. We are more than hospitals, as we have a robust system of care including specialty acute care, over 360 primary care and specialty employed providers, Express Care at Walgreens clinics, urgent care centers, wound care, physical therapy, home care, mobile mammography and more. AdventHealth is a faith-based not-for-profit health care system with a mission of Extending the Healing Ministry of Christ. AdventHealth has hundreds of care sites and more than 50 hospitals across the United States. For more information about AdventHealth, visit AdventHealth.com, or Facebook.com/AdventHealth.

About SpotRx

SpotRx places control of the pharmacy experience back in the hands of consumers. SpotRx is a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery capability.

About MedAvail

MedAvail Holdings, Inc. (NASDAQ: MDVL) is a technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes. Learn more at http://www.medavail.com.

Share article on social media or email:

Russak Dermatology’s Hair Restoration Therapy


Dr. Julie Russak is a board-certified dermatologist and founder of Russak Dermatology Clinic and Russak+ Aesthetic Center.

Significant hair-loss affects 20% of all COVID patients who have been hospitalized. Among those who didn’t have acute symptoms, the percentage may be even higher. It’s troubling, but Russak Dermatology Clinic can help.

About three months after a person recovers from COVID-19, excess clumps of hair come out in one’s hand, stick to the back or clog the shower drain. A brush contains much more hair than normal, or hair litters the bathroom floor or a bed pillow in disturbing amounts.

Some hair loss – about 100 hairs per day – is natural and normal. When that increases to 300 or more hairs per day, something is not right. Post-COVID, if hair thins perceptibly, the condition is called telogen effluvium.

Telogen effluvium is not specific to COVID. It can happen several months after any time the body undergoes stress, such as after a high fever, the flu or another serious illness, so it’s no surprise that it happens to COVID patients. It’s also common during pregnancy and after giving birth, and certain medications can trigger it. However, since the beginning of the pandemic, the incidence of telogen effluvium has increased 400 percent. The hair loss associated with telogen effluvium occurs primarily on the head and excessive shedding can continue for many months.

Scientists have yet to link hair-loss directly to the COVID virus. Most experts agree that the stress related to contracting COVID, anxiety over the disease, job loss, feelings of isolation and depression, and changes in lifestyle due to the pandemic are the real culprits. The good news is that in most cases of telogen effluvium, hair growth and loss return to normal, but it takes a long time, up to a year.

Dr. Julie Russak’s signature Hair Restoration Therapy is a safe, nonsurgical way to stimulate hair growth. The treatment combines Platelet-Rich Plasma (PRP) Therapy, Exosome Stem Cell injections, diffused microneedling and topical and oral supplements. It’s a unique, clinically-proven approach that is more proactive because it delivers these regenerative ingredients into the scalp, awakening hair follicles and stimulating hair growth.

PRP Therapy

Blood platelets contain hundreds of healing proteins called growth factors, which are known for their regenerative qualities. Normally, platelets make up about 10 percent of the blood’s cellular components. In PRP Therapy, that percentage is flipped to 90 percent. When platelet-rich plasma is infused into the scalp, it encourages hair growth at an accelerated rate.

During a Hair Restoration Therapy treatment, first a phlebotomist draws a small sample of the patient’s blood, which is spun in a centrifuge designed to concentrate platelets. In essence, the red and white blood cells are separated from the platelets and plasma (clear-gold fluid), creating PRP. The concentration of platelets in PRP, and thus the concentration of growth factors, can be up to ten times greater than in normal blood.

Once the PRP is isolated, the clinician injects and microneedles the PRP into the scalp. Microneedling ensures the valuable growth factors in the PRP penetrate directly into the hair follicles, and injections allow the PRP to get even deeper into the skin. The growth factors in the PRP then stimulate stem cells around the hair follicles into an active growth phase.

In addition, non-platelet components of the blood plasma are present in lower amounts, and contains nutrients, vitamins, hormones, electrolytes and proteins that are essential to hair health. As a result, hair grows back and at a faster rate than if left only to Mother Nature.

Exosome Booster

Exosomes are a new breakthrough in regenerative hair therapy that triggers healing, cell stimulation and regeneration. Exosomes are extracellular vesicles, or small bubbles, released from stem cells. They contain genetic signals that stimulate cells, in this case healthy hair follicles.

The exosomes released by regenerative cells such as stem cells are potent drivers of repair, regeneration and healing. When hair loss occurs, exosomes signal the follicles to heal themselves which stimulates new hair growth. Exosomes contain bioactive molecules that play a crucial role in cell-to-cell communications and are vital in all cellular regenerative processes. When they are infused directly into the scalp, the result is intensive hair rejuvenation, especially when combined with PRP Therapy.

Reversing Other Types of Hair Loss

Thinning hair can result from many different factors in addition to COVID and stress, including family history, hormonal changes, certain disease and medications, scalp imbalance and more. PRP Therapy enhanced with an Exosome Booster delivers a comprehensive approach to treating hair loss in many situations. Any person who has experienced “miniaturization”, or hair thinning, is an ideal candidate for this proven hair restoration therapy. It’s customized for each patient with the goal of reactivating the hair follicles.

The protocol consists of four sessions spaced one month apart, with maintenance treatments every four to six months after that to keep hair follicles stimulated and to maintain hair growth. These in-clinic treatments are augmented by oral supplements and Russak Dermatology’s proprietary topical spray, called Hair Fortifying RX.

Hair Fortifying RX is a concentrated blend of vitamins and hair regrowth stimulants, including 10% minoxidil, which reduces inflammation around the follicle and stimulates hair regrowth on its own. When combined with Hair Restoration Therapy, the result is fuller, denser hair!

Selected by the New York Times as a “New York Super Doctor”, Dr. Julie Russak, M.D., FAAD, is a board-certified dermatologist, Fellow of the American Academy of Dermatology and the founder/CEO of Russak Dermatology Clinic in New York City. In addition to providing comprehensive care in cosmetic and medical dermatology through the clinic, she serves on the faculty of Mount Sinai Hospital and was awarded Teacher of the Year in 2022. Her expertise includes general, cosmetic and pediatric dermatology, skin cancer and dermatologic surgery. For more information, go to http://www.russakdermatology.com.

Living Magazine readers say Caydance Assisted Living & Memory Care “the best”


“Being voted ‘Best of Assisted Living’ by readers shows how Caydance Assisted Living & Memory Care continues to provide exceptional, expert care to its residents,” Sagora Senior Living Corporate Director of Operations Christal Hoffman said. “Each day,

The vote is in and Caydance Assisted Living & Memory Care, a Sagora Senior Living community in Katy, Texas, took home top honors.

Readers of Living Magazine selected Caydance Assisted Living & Memory Care as “Best of Assisted Living” for the Katy/Fulshear area during its 2022 Readers’ Choice Awards. Living Magazine unveiled the winners as part of its August edition.

“Being voted ‘Best of Assisted Living’ by readers shows how Caydance Assisted Living & Memory Care continues to provide exceptional, expert care to its residents,” Sagora Senior Living Corporate Director of Operations Christal Hoffman said. “Each day, Caydance’s team members personify Sagora’s Resident First philosophy.”

Caydance Assisted Living & Memory Care is located on Kingsland Boulevard in Katy. It offers individualized, adaptive care plans for both Memory Care and Assisted Living residents. Programs are focused on providing residents with a sense of peace, comfort and dignity while allowing them to remain active for as long as possible.

###

ABOUT SAGORA SENIOR LIVING

Sagora Senior Living is among the nation’s top-50 senior housing providers and abides by a Resident-First philosophy. The company operates more than 50 communities in 11 states, with Cottages, Independent Living, Assisted Living and Memory Care living options. For additional information, please visit Sagora.com.

Share article on social media or email:

mTelehealth Partners with Nonagon to Launch Transformative Virtual Telehealth Technology


mTelehealth

mTelehealth

Nonagon’s technology is nine steps ahead of the telehealth world by creating limitless access between patients, caretakers, and healthcare organizations.- Marc Poulshock, President and CEO, mTelehealth

With the mission to strengthen its healthcare services for patients and residents, Vista Grande Villa officially announced the adoption of a game-changing digital telehealth platform, Nonagon, to provide its skilled nursing center with 24/7 access to patients’ health care providers (HCPs) whenever the need arises. Nonagon’s N9 hand-held device enables 9 medical-grade exams to be captured and shared with HCPs, bolstered by Nonagon’s proprietary, HIPAA-compliant, and secure communication platform and database.

The FDA-cleared N9 device communicates with a laptop, tablet, or smartphone for clinical-grade remote examinations of the heart, lungs, abdomen, oxygen saturation (important for diagnosing COVID), ears, mouth/throat, skin, and body temperature. Nonagon automatically documents and shares exam results (via photo, audio, video, or text-based message) to physicians which can help in improving health outcomes, reducing visits to the Emergency Room and reducing readmissions.

The integration of Nonagon into Vista Grande Villa’s skilled nursing center’s infrastructure, provided by mTelehealth, comes as part of a grant awarded to Vista Grande Villa and two other Health Care Providers by the FCC COVID-19 Telehealth Program, using telecommunication technology to reduce patients’ unnecessary risk of exposure to infectious disease and other dangers related to leaving the facility during recovery.

“For any telehealth solution to be successful in supporting senior living communities and nursing care facilities, it needs to give clinicians the tools capable of painting a clear clinical picture, but more critically, the ability for a nurse and provider to have a discussion,“ according to mTelehealth CEO Marc Poulshock. “Nonagon’s technology is nine steps ahead of the telehealth world by creating limitless access between patients, caretakers, and healthcare organizations.”

Vista Grande Villa is a 318-unit non-profit senior living community offering independent living, assisted living, memory care, and skilled nursing care.

“Since 1972, Vista Grande Villa has been committed to providing the best senior living experience in Jackson, Michigan and we are continuing that legacy by integrating Nonagon’s world-class telehealth services into our already successful health care,” said Vista Grande Villa Executive Director Chelsea Eisele. “Going forward, Vista Grande Villa’s skilled nursing center will be able to connect, consult, and access a more accurate level of diagnoses from physicians, as if they are on site. This will complement our existing on-site physician visits.”

“When Kauhale Healthcare began management of Vista Grande Villa in March 2022, we committed to bringing the best technology available to the campus and we believe that the Nonagon platform is just that, the best,” said Jim Palculict, COO of Kauhale Healthcare. “We looked at a number of options to telecommunicate with physicians and the one that stuck out is Nonagon because it provides so much more than a HIPAA-compliant video chat, it actually facilitates an intimate, informative virtual exam, and it is surprisingly cost-effective considering all that it does.”

“We are happy to serve the Vista Grande Villa community with our platform that caters to the needs of seniors as a multi-functional, cost-efficient, and accurate solution that can be carried in the palm of the hand while being versatile and adjustable to any type of organization,” according to Nonagon’s CEO Alon Natanson, “The minds behind this platform built it to benefit patients from infants to senior citizens, physicians of various specializations, and healthcare organizations — no matter how large or small. Nonagon is an all-in-one solution for all.”

About mTelehealth

mTelehealth, LLC, founded in 2010 and based in Delray Beach, FL, is a premier provider of Remote Patient Monitoring (RPM), Remote Therapeutic Monitoring (RTM), Telemedicine, Chronic Care Management (CCM), Virtual Exam, Video Visit, and related Telehealth solutions. Our Remote Health Monitoring System, Powered by aTouchAway™, provides a complete solution to remotely collect, store, and report timely and accurate health information anywhere. Furthermore, the innovative, cutting-edge, Nonagon N9 device and platform powers our virtual exam creating limitless access between healthcare organizations and their patients by bringing the clinician “into the room” with the patient like no other telehealth solution. We connect patients with their families and care providers through our easy-to-use, affordable, telehealth devices and platforms. For more information, visit their website: https://mtelehealth.com, Facebook, LinkedIn, and Twitter.

About Nonagon

Nonagon is a fast-growing medical device company, with offices based in Israel (HQ) and the United States. Nonagon seeks to make remote digital medicine clinically reliable and accessible to the community in the fields of family, chronic, and pediatric and is pursuing that by introducing new digital enhancements and creating new opportunities for better patient care. For more information, visit http://www.nonagon-care.com.

About Vista Grande Villa

Founded in 1972, Vista Grande Villa has been providing residential and care services to seniors in the Jackson region for more than 50 years. With its new management under Kauhale Healthcare, Vista Grande Villa ensures that the senior community will experience quality services and care while embracing individual choice and independence. For more information, visit: https://vistagrandevilla.com.

About Kauhale Healthcare Management

Founded in 2021, Kauhale Healthcare Management (kauhalehealth.com) is a Midwest-based firm led by five principals with a combined 130 years of experience in senior living/integrated post-acute care operations, acquisitions, operational transfers, and development. Their team has experience across 20 U.S. states, including management responsibilities for more than 300 stand-alone Independent Living (IL), Assisted Living (AL), Memory Care (MC), Skilled Nursing Facility (SNF), and Continuing Care Retirement Community (CCRC) properties.



American College of Lifestyle Medicine Announces CME/CE Credit Hours, Lifetime Achievement Honorees for Annual Conference Nov. 13-16 in Orlando


News Image

“The national conference will jumpstart all providers looking for the knowledge and implementation strategies to improve patient care and rebuild healthcare better.”

The American College of Lifestyle Medicine (ACLM) today announced up to 41.5 possible in-person and virtual general CME/CE credit hours for its 2022 Lifestyle Medicine Annual Conference, to be held November 13 to 16, 2021, at the Rosen Shingle Creek Resort in Orlando, FL. The hybrid event, “Rebuilding Healthcare Better,” will showcase practical ways lifestyle medicine is changing the face of medical education and clinical practice to restore health to those living with chronic diseases. As part of the event, ACLM will honor Jack LaLanne (posthumously) and Elaine LaLanne and Kenneth Cooper, MD, with its Lifetime Achievement awards.

Both in-person and virtual conference attendees have the opportunity to earn up to 41.5 hours of continuing medical education, including AMA PRA Category 1 Credit™️. Credit hours are available for physicians, nurses, pharmacists, psychologists, occupational therapists, physical therapists, dietitians and health and wellness coaches.

Recognizing exceptional achievement and contributions to advocating for exercise in medicine, a key pillar of lifestyle medicine, the 2021 Lifetime Achievement Award will be presented posthumously to “godfather of modern fitness” Jack LaLanne and to his wife, Elaine, with the 2022 award presented to the “father of aerobics” Dr. Kenneth Cooper.

Conference speakers will include: 20th U.S. Surgeon General Jerome Adams, MD, MPH, FASA; gut health expert Will Bulsiewicz, MD, MSCI; food policy expert and author Marion Nestle, PhD, MPH; New York Health Plan and Hospitals CEO Michael Katz, MD; Forbes contributor, author, Stanford Medical School faculty member and former CEO of The Permanente Medical Group, Robert Pearl, MD; as well as Institute for Advancing Health Value Executive Director Eric Weaver, DHS, MHA.

Serving as the annual conference of the nation’s fastest growing medical professional association, LM2022 is for primary care and specialist physicians, physician assistants, nurses, nurse practitioners, pharmacists, dietitians, exercise physiologists, physical therapists, occupational therapists, respiratory therapists, social workers, speech audiologists, psychologists, health coaches, healthcare executives, students, residents and others seeking to learn more about lifestyle medicine and/or establish or grow lifestyle medicine practices.

In addition to its line-up of keynote speakers, the conference will include concurrent sessions, pre- and post-conference workshops, an exhibitor pavilion, the annual Lifestyle Medicine Celebration reception and awards ceremony, and networking opportunities with like-minded medical professionals and industry leaders. Concurrent sessions for the in-person event will be offered in tracks for the first time: Allied Health Professionals; the Business of Lifestyle Medicine; the Science of Lifestyle Medicine; and the “How” of Lifestyle Medicine.

A wide array of both pre- and post-conference in-depth workshops will be offered as part of the registration process at an additional registration fee. These will cover topics such as lifestyle medicine in community healthcare as well as in healthcare systems; behavior change science; workforce well-being; pediatric obesity; the lifestyle medicine education spectrum; women’s health; lifestyle medicine protocols and standardization in care; shared medical appointments; and optimizing exercise for all.

“This year’s conference promises to be a premier convener for lifestyle medicine subject matter experts, thought leaders and clinicians passionate about rebuilding healthcare better,” said ACLM President Cate Collings, MD, MS, FACC, DipABLM. “More than ever before, lifestyle medicine is recognized for value in solving for the mismatch between health care outcomes and health care costs at the national health care policy level and at the health system level. I get more excited every year knowing that the national conference will jumpstart clinicians and all providers looking for the knowledge and implementation strategies to improve their patient care and rebuild healthcare better from the ground up with a lifestyle first approach.”

For more information about LM2022, accreditation information, exhibit sponsorship opportunities, or to register, see https://lmconference.org/.

In-person and virtual general registration (not including workshops) until August 29th will be: $849 for members and $1,099 for nonmembers. From August 30 to November 13, pricing increases to $949 for members and $1,199 for nonmembers.

General in-person event registration will close September 23 or when the 1,900-person maximum in-person capacity for the main ballroom is reached. Virtual registration will remain open during the conference.

Pre- and post-conference workshop pricing for the three-hour workshops is $120 for members and $170 for non-members. Pre- and post-conference workshop registration will close on November 1, 2022, or when capacity is reached for each workshop. Workshop registration is not available for virtual attendees and the workshops will not be recorded.

Student and resident in-person pricing is $499 for members and $599 for nonmembers. Virtual student and resident registration is $49 for members and $149 for non-members. Those who verify enrollment in an academic program (at least 1/2 time) or employment through a residency program qualify for specially discounted LM2022 registration rates. To submit your enrollment or employment documents to apply for the LM2022 trainee discounted registration please use this form.

ABOUT THE AMERICAN COLLEGE OF LIFESTYLE MEDICINE: The American College of Lifestyle Medicine is the nation’s medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health. ACLM educates, equips, empowers and supports its members through quality, evidence-based education, certification and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management.

LM2022 Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

This activity is being presented without bias and without commercial support.

Rush University Medical Center designates this live activity for a maximum of 41.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this live activity for a maximum of 41.5 nursing contact hour(s).

Rush University Medical Center designates this knowledge-based live activity for a maximum of 16.75 contact hour(s) for pharmacists.

Rush University Medical Center designates this activity for 41.5 CE credits in psychology.

Rush University is an approved provider for physical therapy (216.000272), occupational therapy, respiratory therapy, social work (159.001203), nutrition, speech-audiology, and psychology by the Illinois Department of Professional Regulation.

Rush University designates this live activity for a maximum of 41.5 continuing education credits for physical therapists, occupational therapists, respiratory therapists, social workers, nutritionists, speech pathologists, audiologists, and/or psychologists.

This activity has been approved by the Commission on Dietetic Registration for 41.5 CPEUs.

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

The LM2022 General Conference is an Approved CE Course (CEA-000093-1) by the National Board for Health and Wellness Coaching (NBHWC). Up to 41.5 CE can be earned through this Approved CE Course; CE will be distributed commensurate with actual attendance.

Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors


“Although there has been marked improvement in treatment options for patients with these tumors, most patients either do not respond to these therapeutics or develop early resistance,” said Fred R. Hirsch, MD, PhD, Executive Director of the Center for Thoracic Oncology at Mount Sinai Health System.

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.

KRAS mutations are among the most common observed in lung cancer and are found in approximately 30 percent of non-small cell lung cancers (NSCLC). NSCLCs with KRAS mutations are associated with a 35 percent higher risk of death than other NSCLCs. Although there has been marked improvement in treatment options for patients with these tumors, most patients either do not respond to these therapeutics or develop early resistance. Thus, there is still a need for curative therapeutic options.

“Typically, when patients with advanced NSCLC with a KRAS mutation receive therapeutics, there is a period of regression and then the cancer recurs, which is the paradigm in lung cancer more generally. The idea behind our proposal is to explore whether we can use a targeted therapeutic agent called a RAF inhibitor to silence that pathway in these tumors and whether that creates a vulnerability that we can exploit to kill the cancer by using another therapeutic agent,” said Principal Investigator Fred R. Hirsch, MD, PhD, Executive Director of the Center for Thoracic Oncology, and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.

One reason for the higher risk of cancer-related death among patients with KRAS-mutant lung cancers is an inability to effectively silence tumor survival signaling through direct targeting of the mitogen-activated protein kinase (MAPK) pathway, which plays a key role in the development and growth of tumors.

Through the SU2C Catalyst® grant, Mount Sinai researchers will partner with Kwok-Kin Wong, MD, PhD, co-Principal investigator and Anne Murnick Cogan and David H. Cogan Professor of Oncology in the Department of Medicine and director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, to identify potential therapeutic combinations that build on the impact of JZP-815, a novel pan-RAF inhibitor that has been shown to enhance the effect of other therapeutic agents in treating KRAS-mutant NSCLC.

“With this collaborative grant, we have the impetus and ability to bring together Mount Sinai’s diverse patient population and expertise in organoid modeling with NYU’s extensive background in mouse modeling to explore questions we would not have been able to investigate independently,” said co-lead investigator Benjamin D. Hopkins, PhD, Assistant Professor of Genetics and Genomic Sciences, and Oncological Sciences, at Icahn Mount Sinai, and co-leader of the Functional Genomics Pipeline at The Tisch Cancer Institute. “Together, we have the potential to develop new treatment strategies for KRAS-mutant lung cancer patients who are in critical need of improved clinical options. We are grateful to Stand Up To Cancer for making this undertaking possible.”

Drawing on Mount Sinai’s functional genomics pipeline, researchers will use genetically engineered KRAS-mutant mouse-derived cell lines to identify JZP-815-related changes that result in vulnerabilities that can then be exploited with other therapeutic agents to effectively kill the tumor.

The researchers will then validate these therapeutic combinations using both patient-derived organoids—three-dimensional cultures of tumor cells—and mouse models to further assess their impact on tumor growth and development. They will also validate potential biomarkers that will help identify patients who are likely to respond favorably to a particular therapeutic combination, thus increasing the likelihood of positive outcomes.

“The goal for all cancer researchers is to improve patient care by identifying therapeutic agents that either are curative or deliver better results than the standard of care,” Dr. Wong said. “We are excited to work toward this goal for a cancer that is more aggressive and is associated with a poorer prognosis than other lung cancers.”

Stand Up To Cancer raises funds to accelerate the pace of cancer research to get new therapies to patients quickly to save lives now. SU2C Catalyst grants provide funding for collaborative signal-finding clinical trials supported by industry leaders. This grant is made possible with support from Jazz Pharmaceuticals. For more information about these grants, visit https://progress.standuptocancer.org/catalyst.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in 4 out of 10 pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

Aesthetics Biomedical® Inc. Announces Issuance of its Third U.S. Patent for “Biological Preserving Composition and Methods of Use” for its SoME® Skincare Product Line.


“This latest, additional patent for preserving biologics marks a paradigm shift for skincare and adds additional protection to Aesthetics Biomedical’s product portfolio”, Shaun Wootten, Director of Innovation and Design.

Aesthetics Biomedical® Inc (ABM), a leader in regenerative medicine and advanced aesthetics committed to the development and distribution of breakthrough, novel, and personalized aesthetic devices and products announces the issuance of its third US patent for “Biological Preserving Composition and Methods of Use” from the United States Patent Trademark Office. The newly issued [third] patent continues the protection of its innovation in the proprietary topical compositions of its SoME® Skincare product which combines with physician infused biologics and presents the future of personalized skincare.

Founder & Chief Executive Officer, MaryAnn Guerra says of the issuance “Once again, I am excited to see that Aesthetics Biomedical’s innovations have been validated by the issuance of a new patent, further strengthening our SoME® Skincare brand and patent portfolio. Our SoME® Skincare product line will be expanded to fully utilize the broader patent coverage, under the leadership of our Director of Innovation & Design, Shaun Wootten.”

SoME® Skincare, medically dispensed through professional offices, with its unique technology platform combines the body’s own regenerative cytokines within skincare. Proven in skin renewal and regeneration, SoME® Skincare is clinically shown to improve both visual and cellular facial aging. “This latest, additional patent for preserving biologics marks a paradigm shift for skincare and adds additional protection to Aesthetics Biomedical’s product portfolio”, said Shaun Wootten, Director of Innovation and Design. “This is Aesthetics Biomedical’s broadest patent yet on the matter and cements the ingenuity of our Center of Aesthetic Innovation.”

The growth factors, derived from Platelet Rich Plasma [PRP] infused within its advanced formula signals the biochemical receptors on the cell surface to stimulate new collagen and new elastin critical for regeneration and repair of photodamaged skin to produce a personalized, autologous skincare treatment. Aesthetics Biomedical® Inc. is continuing to build its pipeline of regenerative products with a focus on skin, hair, and nail personalized products. The patents cover multiple delivery systems including, gel, cream, ointment, and spray. This is coupled with the PRP serving as a rich source of exosomes that provide a natural comprehensive means for regeneration. According to Lawrence A Rheins PhD, Chief Scientific Officer, “The additional patent protection offered for SoME® Skincare, will continue to provide Aesthetics Biomedical® with a unique technology platform consisting of stabilized platelet rich plasma, permitting Aesthetics Biomedical® to develop a multitude of topical products for various skin conditions including facial anti-aging.”

ABOUT AESTHETICS BIOMEDICAL®: Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical’s innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network, and the aesthetic arena, creating novel and unique patient experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. For more information, please visit [AestheticsBiomedical.com.

Share article on social media or email:

iPulser Launches New Device & App to Help Ease Chronic Pain


News Image

“These innovative personalized medical technologies use a self assessment process that leverages an individual’s autonomic nervous system profile to guide decisions regarding the prevention, diagnosis, and treatment of an ailment.”

iPulser has launched the iPulser device and app system to give users a very simple and personalized remedy at the cellular level to help ease chronic pain. The iPulser system ($299.95 at the iPulser website) utilizes an FDA approved drug-free technology known as PEMF (Pulse Electro-magnetic Field).

PEMF therapy interacts with your Autonomic Nervous System to restore the body’s own means for health and healing. Working together with the compact, disc-shaped device, the iPulser app is a simple, intuitive tool that guides users through a self-assessment, after which an advanced Artificial Intelligence process identifies a user-specific treatment and also provides tracking of the personalized iPulser programs.

A recent large study of iPulser users delivered outstanding results. 86% of patients reported a significant reduction in the intensity of their pain; 71% reported a significant reduction in the frequency of their pain, and 63% reported a significant improvement in mobility.

Dr. Joshua Prager, Medical Director of iPulser and Director of the UCLA Center for Rehabilitation of Pain Syndromes, notes, “We bring a patient-focused approach to the field of medical technologies, to create an experience that promotes health and wellbeing. These innovative personalized medical technologies use a self assessment process that leverages an individual’s autonomic nervous system profile to guide decisions regarding the prevention, diagnosis, and treatment of an ailment. Ultimately, this helps users live a better, more pain-free, more enabled life.”

To learn more, please contact Jeannine Jacobi of Fresh PR at 323-903-7063 or jeannine@freshpr.net, or visit https://www.ipulser.com.

About iPulser

iPulser has created a device and app system that gives users a very simple and personalized remedy at the cellular level to help ease chronic pain. The system utilizes an FDA approved drug-free technology known as PEMF (Pulse Electro-magnetic Fields). PEMF therapy interacts with your Autonomic Nervous System to restore the body’s own means for health and healing. Working together with the compact, disc-shaped device, the iPulser app is a simple, intuitive tool that guides users through the formulation, application, and tracking of personalized iPulser treatment programs. A recent large study of iPulser users delivered outstanding results. 86% of patients reported a significant reduction in the intensity of their pain; 71% reported a significant reduction in the frequency of their pain, and 63% reported a significant improvement in mobility. Ultimately, this helps users live a better, more pain-free, more enabled life.

Share article on social media or email:

KiwiTech Announces Strategic Partnership With Healthcare Startup Making Baby Connection


KiwiTech, LLC, a startup ecosystem that helps early to growth-stage startups with technology, fundraising, and go-to-market support, entered into a strategic partnership with Making Baby Connection. This California-based healthcare startup is an exclusive one-stop service for people’s surrogacy and fertility needs.

“We are excited to begin our professional relationship with Making Baby Connection. Their unique solution to surrogacy and fertility needs positions them as an exclusive platform to help families navigate the surrogacy process. We look forward to providing our technical expertise and guidance in building this one-of-a-kind startup.,” said Rakesh Gupta, CEO, and Founder, KiwiTech.

“We are delighted to collaborate with KiwiTech,” said Evie Jeang, Founder & CEO of Making Baby Connection. “We look forward to building this mission-led startup that aims to open the newer options for prospective parents to have babies. Make Baby Connection aims to simplify the process of surrogacy, which is complicated and tedious on multiple fronts, such as financial, legal, and emotional. We have full faith that KiwiTech can help us further and guide us in reaching more people faster and adding value in their lives.”

About KiwiTech

KiwiTech is a growing ecosystem of entrepreneurs, investors, and mentors. The company helps early and growth-stage startups build viable products, drive traction, raise capital, and scale their businesses. KiwiTech is home to 500+ portfolio companies across 15+ industries undergoing disruption and takes pride in its 600+ strong team with extensive experience in emerging and existing technologies.

About Making Baby Connection

Making Baby Connection is an exclusive one-stop service for people’s surrogacy and fertility needs. Understanding the complexities that can come with growing a family in a non-traditional manner, Making Baby Connection aims to make this exciting venture effortless for people looking forward to starting a family.

Share article on social media or email: